Maintenance bevacizumab–pemetrexed after first-line cisplatin–pemetrexed–bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial-Reference-Cited by-同舟云学术

Maintenance bevacizumab–pemetrexed after first-line cisplatin–pemetrexed–bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial

Published:2014-05 Issue:5 Volume:25 Page:1044-1052
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Barlesi F.,Scherpereel A.,Gorbunova V.,Gervais R.,Vikström A.,Chouaid C.,Chella A.,Kim J.H.,Ahn M.J.,Reck M.,Pazzola A.,Kim H.T.,Aerts J.G,Morando C.,Loundou A.,Groen H.J.M.,Rittmeyer A.

Funder

F. Hoffmann-La Roche, Ltd

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/25/5/1044/368426/mdu098.pdf

Reference22 articles.

1. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer;Schiller;N Engl J Med,2002

2. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results;Breathnach;J Clin Oncol,2001

3. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer;Sandler;N Engl J Med,2006